Form 4: Arvinas CMO Sells Shares for Tax Obligations

Arvinas Chief Medical Officer Noah Berkowitz sold 6,435 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Noah Berkowitz, Chief Medical Officer of Arvinas, Inc. (ARVN), reported a sale of common stock.
• The transaction involved the disposition of 6,435 shares of Arvinas common stock.
• The shares were sold at a price of $11.1004 per share.
• This sale was non-discretionary and automatically executed by the Issuer to cover tax withholding obligations.
• The tax obligations arose from the vesting and settlement of 25% of Mr. Berkowitz's restricted stock units (RSUs) granted on March 18, 2024.
• Following this transaction, Mr. Berkowitz beneficially owns 202,503 shares of Arvinas common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event because the sale was non-discretionary and solely for tax purposes, not reflecting a change in the insider's investment outlook or the company's fundamentals.

Positives

• The sale was explicitly stated as non-discretionary, indicating it was not driven by a change in the insider's sentiment towards the company's prospects but rather a routine tax event.

Negatives

• The transaction represents a reduction in direct insider ownership, albeit for a specific tax-related purpose.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sale was made automatically by Arvinas, Inc. to cover tax withholding obligations in connection with the vesting and settlement of 25% of the reporting person's restricted stock units (RSUs) granted on March 18, 2024.
• The sale does not represent a discretionary trade by Noah Berkowitz.

Industry Context

StockSavvy.ai notes that sales of company stock by executives to cover tax withholding obligations upon the vesting of restricted stock units (RSUs) are a common and routine occurrence in the biotechnology and pharmaceutical industries. These transactions are typically non-discretionary and are generally not interpreted as a signal of an insider's negative outlook on the company's future prospects, unlike open market discretionary sales.

Stakeholder Impact

• Shareholders: The impact is minimal as the sale is a routine, non-discretionary event for tax purposes and does not signal a change in management's confidence or the company's operational outlook.

Key Dates

Recommendation

The transaction is a routine, non-discretionary sale to cover tax obligations upon RSU vesting, which does not signal any change in the company's fundamentals or the insider's long-term view. Therefore, it does not warrant a change in investment posture based solely on this filing.

Keywords

Arvinas, ARVN, Insider Trading, Form 4, Stock Sale, Tax Withholding, RSU Vesting, Noah Berkowitz, Chief Medical Officer